CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Portland, Oregon, United States and 83 other locations
This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects ...
Phase 1
Portland, Oregon, United States and 12 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Portland, Oregon, United States and 904 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Portland, Oregon, United States and 33 other locations
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemipl...
Phase 1, Phase 2
Portland, Oregon, United States and 12 other locations
plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treat...
Phase 3
Vancouver, Washington, United States and 152 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
Vancouver, Washington, United States and 219 other locations
of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer...
Phase 2
Vancouver, Washington, United States and 117 other locations
with standard chemotherapy for the potential treatment of colorectal cancer that:* has spread to other parts of the body (metastatic);* has ...
Phase 3
Portland, Oregon, United States and 408 other locations
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...
Phase 3
Vancouver, Washington, United States and 393 other locations
Clinical trials
Research sites
Resources
Legal